Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial

Thumbnail
URI
https://rde.dspace-express.com/handle/11287/621675
Author
Withers, Nicholas J.
Date
2021-02-01
Journal
American Journal of Respiratory and Critical Care Medicine
Type
Clinical Trial, Phase III
Publisher
Atypon
DOI
10.1164/rccm.202008-3176LE
Rights
Copyright © 1987-2020 American Thoracic Society, All Rights Reserved.
Metadata
Show full item record
Citation
Griese M et al. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021 Feb 1;203(3):381-385.
Publisher URL
https://www.atsjournals.org/doi/10.1164/rccm.202008-3176LE?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
Collections